oxymorphone trials begin, page-26

Forgot to add... firstly, from Pfizer’s website, the what and when of its areas of interest for partnering in biopharmaceuticals.

Pfizer's goal is to continue to lead in Primary Care through effective and efficient delivery of our portfolio today, and continued innovation to meet customer and patient needs as healthcare systems transform around the world.

Our... business units generally are responsible for late-stage clinical development of investigational medicines that have advanced to at least phase 2b of clinical development, having achieved earlier stages of pre-identified safety and efficacy measures.

Our focus is on high-need disease areas such as Pain...



And then Purdue’s declared area of interest for in-licensing...

Purdue’s licensing strategy seeks to identify late-stage products within the following therapeutic areas:

Pain management – both non-opioids and opioids


According to Endo Pharmaceuticals its key revenue drivers in 2012 were the branded pharmaceuticals, Opana ER (oxymorphone) and Voltaren gel (diclofenac). It also identifies Lidoderm (lidocaine) as a key component of its core business (POH has already successfully demonstrated superior delivery of lidocaine). Endo nominates pain as a key therapeutic area of interest for partnering. Now there’s a pharma with a whole lot to lose...or gain.


Johnson and Johnson is more coy about publicly declaring its areas of interest for partnering. However, with relentlessly declining sales and a chequered history of lawsuits and recalls with the Duragesic patch, one would imagine Johnson and Johnson might be seeking a way out. Add them to the list...


Novartis states that it is seeking development opportunities with novel delivery technologies for oral, topical and transdermal products.
By now I think you know which company fits that description.


All proof that POH would be well justified in playing hard to get...




http://www.pfizer.com/partnering/areas_of_interest/biopharmaceuticals.jsp


http://www.purduepharma.com/about/partner-with-purdue/


http://www.faqs.org/sec-filings/120109/ENDO-PHARMACEUTICALS-HOLDINGS-INC_8-K/d279229dex992.htm#b


http://pharmalicensing.com/public/inlicensing/view/3247/seeking-development-opportunities-with-novel-delivery-technologies-for-oral-topical-and-transdermal-products